RESUMO Objetivo: Avaliar a capacidade funcional e a qualidade de vida de crianças e adolescentes em tratamento e pós-tratamento oncológico. Métodos: Estudo transversal de pacientes com câncer em tratamento ou pós-tratamento oncológico avaliados pelo teste de caminhada de 6 minutos (TC6) e pelo questionário Pediatric Quality of Life™ (módulo câncer). Resultados: Sessenta e cinco pacientes, com idade de 11,2±3,5 anos, sendo 50,8% do sexo masculino e 90,8% da raça branca, participaram do estudo, com mais incidência para os tumores hematológicos (81,5%). O desempenho no TC6 foi 23,1% inferior, quando comparadas as médias predita e realizada (584,3±5 m e 447,7±78,6 m, respectivamente). A diferença percentual entre o predito e o realizado do TC6 e as várias fases do tratamento oncológico foi significativa tanto entre os pacientes em tratamento (73,7±12,8%) como em pós-tratamento (84,5±9,1%). Quando separados os pacientes pelos diferentes diagnósticos, observou-se que a distância percorrida por aqueles com leucemia apresentou o resultado mais próximo do predito (80,7±11,7 m). No que diz respeito ao questionário sobre qualidade de vida relacionada à saúde (QVRS), a percepção da criança (78,0±14,5) foi melhor do que a relatada pelos pais (72,4±17,7). Mas, na comparação da QVRS com o TC6, não foi encontrada nenhuma associação (p=0,597). Conclusões: Crianças e adolescentes em tratamento ou pós-tratamento oncológico apresentaram déficit de 23% na capacidade funcional. Na comparação dos resultados da QRVS, a percepção das crianças foi superior à dos pais.

ABSTRACT Objective: To evaluate the functional capacity and quality of life of children and adolescents during cancer treatment and post-treatment. Methods: Cross-sectional study of patients during cancer treatment and post-treatment, assessed by the 6-minute walk test (6MWT) and the Pediatric Quality of Life ™ questionnaire (cancer module). Results: Sixty-five patients, aged 11.2±3.5 years, mostly males (50.8%) and white (90.8%), with high incidence of hematological cancers (81.5%) participated in the study. The performance in the 6MWT was 23.1% inferior comparing the mean predicted and achieved (584.3±5 and 447.7±78.6 m, respectively). The percentage difference between the predicted and achieved 6MWT, and the different phases of cancer treatment were significantly different between patients in treatment (73.7±12.8) and post-treatment (84.5±9.1). When grouped by the different diagnoses, it was possible to observe that the distance covered by the patients with leukemia showed results closer to that predicted (80.7±11.7). Regarding the health-related quality of life questionnaire (HRQL), the child’s perception (78.0±14.56) was better than that reported by their parents (72.4±17.74). However, when we compared HRQL with the 6MWT, there was no association between them (p=0.597). Conclusions: Children and adolescents undergoing cancer treatment or post-treatment showed a 23% deficit in functional capacity. In relation to HRQL results, children’s perception was higher than that of their parents.

Phase transitions, thermal stability, thermokinetics and activation parameters of degradation reaction of the dicationic ionic liquids (ILs), 1,n-bis(3-methylimidazolium-1-yl)alkane ([BisAlk(MIM)2][2Br]) and monocationic ILs, 1-(3-methylimidazolium-1-yl)alkane ([Alk(MIM)][Br]), where Alk = Dec, DoDec, TetDec, (decane, dodecane, tetradecane) were evaluated. The influence of an additional cationic head and the alkyl chain length in thermal parameters were also evaluated. The dicationic ILs are more stable than monocationic and thermal degradation of ILs mono- and dicationic did not show linear dependence on the alkyl chain length. Thermokinetic parameters indicated degradation in multiple steps. The monocationic ILs showed a more persistent crystalline phase than dicationic IL, which became totally amorphous after heating. The estimate temperature decomposition, activation energy and thermal transitions enable the determination of which types of ILs are applicable for specific purposes, such as lubricants or solvents at high temperatures, while maintaining ILs physical and chemical properties.

A series of twelve novel 2-(pyrazol-1-yl)pyrimidine derivatives was easily obtained under ultrasonic conditions by the cyclocondensation reaction of 1-carboxamidino-pyrazoles with 4-methoxyvinyl-trifluoromethyl ketones using ethanol as an environment-friendly solvent in the presence of potassium hydroxide. Comparison of the ultrasound-promoted reaction with classical methodology shows that the former is faster and gives better yield. The products were isolated in excellent purity grades without purification by chromatography or recrystalization.

Uma série de novas pirazolinas N-acil trialometiladas derivadas de ésteres metílicos de ácidos graxos foi sintetizada por reação de ciclocondensação entre hidrazidas graxas e 4-alcóxi-1,1,1-trialometil-3-alquen-2-onas. Ciclizações eficientes e regioespecíficas catalisadas por BF3·MeOH levaram aos produtos desejados em rendimentos de bons a excelentes e alto grau de pureza.

A series of new fatty N-acyl trihalomethylated pyrazoline derivatives from fatty acid methyl esters was synthesized by the cyclocondensation of respective fatty hydrazides with 4-alkoxy-1,1,1-trialomethyl-3-alquen-2-ones. Efficient and regiospecific cyclizations catalyzed by BF3·MeOH gave the desired products in good to excellent yields and at high purity.